Rare Liraglutide-Induced Dermatological Adverse Reaction in the Treatment of Obesity

Abstract

Liraglutide is a glucagon-like peptide-1 (GLP-1) agonist widely used for managing type 2 diabetes mellitus and obesity. Although allergic reactions to the drug have been documented, skin-related adverse effects remain underreported. We present a case of a 43-year-old woman undergoing subcutaneous liraglutide injections for obesity treatment. Approximately 3 weeks into the treatment regimen, the patient experienced a distinctive reaction characterized by oval, red erythema accompanied by swelling, itchiness, and skin warmth around the injection site shortly after drug administration. This reaction recurred with each subsequent dose over the next 3 days, prompting the patient to discontinue treatment. A dermatology consultant suggested oral antihistamines in conjunction with topical methylprednisolone. Over the course of several days, the intensity of the skin lesions gradually decreased, ultimately resolving completely within 1 month. This case highlights the rarity of skin adverse reactions associated with liraglutide and underscores the importance of recognizing and managing injection site erythema as a potential side effect of this medication. Further research is needed to better understand and document such reactions for improved patient care and safety.

Keywords

diabetes mellitus - drug-induced skin reaction - glucagonlike peptide-1 - obesity treatment

Patient Consent Statement

The authors certify that they have obtained all appropriate patient consent forms, including the format for her images and other clinical information to be reported in the publication. The patient understands that her name and initials will not be published and that every effort will be made to conceal their identity, even when anonymity cannot be guaranteed.

Authors' Contributions

M.M.A. contributed to conception and design of the study; acquisition, analysis, and interpretation of data; and drafting of the manuscript; and final approval of the submitted version of the manuscript. G.R.N. and R.A.R.J. contributed to analysis and interpretation of data, drafting of the manuscript, and final approval of the submitted version of the manuscript.

Publikationsverlauf

Artikel online veröffentlicht:
12. August 2024

• References

• 1 US Food and Drug Administration (FDA); Saxenda (Liraglutide [rDNA origin] Injection). Silver Spring, MD:: FDA; 2015
• 2 European Medicines Agency (EMA); Saxenda. Liraglutide. Amsterdam: EMA; 2018
• 3 Astrup A, Carraro R, Finer N. et al; NN8022-1807 Investigators. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2012; 36 (06) 843-854
• 4 US Food and Drug Administration (FDA); VICTOZA® (Liraglutide) Injection, for Subcutaneous Use Initial U.S. Approval: 2010. Silver Spring, MD:: FDA; 2010
• 5 Neel NF, Ghobara Y, Turkmani M. Liraglutide-induced injection site reaction. J Dermatol Dermatol Surg 2019; 23: 97-98
• 6 Iepsen EW, Torekov SS, Holst JJ. Liraglutide for type 2 diabetes and obesity: a 2015 update. Expert Rev Cardiovasc Ther 2015; 13 (07) 753-767
• 7 Besemer F, Verschoor AJ, Diamant M, Hoogma RP. Vesiculopustular dermatosis: an uncommon side-effect of liraglutide?. J Diabetes Complications 2012; 26 (05) 458-459
• 8 Cogen AL, Desai K, Elder D, Rosenbach M. Acute photodistributed exanthematous pustulosis associated with liraglutide treatment. JAMA Dermatol 2019; 155 (10) 1198-1200
• 9 Bovijn L, Arianayagam S, Asher R. An unusual case of a generalised cutaneous drug reaction to liraglutide. Eur J Dermatol 2019; 29 (06) 675-677
• 10 U.S. Food and Drug Administration; Highlights of Prescribing Information. Full Prescribing Information. SAXENDA (Liraglutide) Injection, for Subcutaneous Use Initial U.S. Approval: 2010. Silver Spring, MD:: FDA; 2010
• 11 Shamriz O, NaserEddin A, Mosenzon O, Sviri S, Tal Y. Allergic reaction to exenatide and lixisenatide but not to liraglutide: unveiling anaphylaxis to glucagon-like peptide 1 receptor agonists. Diabetes Care 2019; 42 (09) e141-e142
• 12 Bode B. An overview of the pharmacokinetics, efficacy and safety of liraglutide. Diabetes Res Clin Pract 2012; 97 (01) 27-42
• 13 Carvallo A, Silva C, Gastaminza G, D'Amelio CM. Delayed hypersensitivity reaction to liraglutide: a case report. J Investig Allergol Clin Immunol 2020; 30 (05) 367-369